Clinical Trial Update: A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia [Phase 3]

View source ↗

Summary

Phase 3 trial update for ianalumab in previously treated warm autoimmune hemolytic anemia (wAIHA) assessing efficacy and safety; status ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Warm Autoimmune Hemolytic Anemia

Drugs mentioned

• Ianalumab (ianalumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Warm Autoimmune Hemolytic Anemia (wAIHA) | Phase 3 | Status: ACTIVE_NOT_RECRUITING